Endocrinology Referral for Elevated DHT and Hair Loss
Yes, refer this patient to endocrinology for comprehensive evaluation of androgen excess, as elevated dihydrotestosterone with hair loss warrants systematic investigation to exclude underlying endocrine pathology that could impact long-term health outcomes 1, 2.
Rationale for Referral
The 2019 Androgen Excess and PCOS Committee guidelines explicitly recommend that women with female pattern hair loss (FPHL) should have circulating androgens evaluated 1. When DHT is already documented as elevated, this represents confirmed biochemical hyperandrogenism requiring endocrine expertise.
Key Considerations Supporting Referral:
Diagnostic Complexity:
- While DHT elevation may reflect local follicular sensitivity rather than systemic overproduction 3, distinguishing between benign androgen sensitivity and pathologic androgen excess requires specialized evaluation
- The 2025 Society for Endocrinology guideline emphasizes that severe androgen excess may indicate underlying adrenal or ovarian neoplasms, genetic disorders, or severe insulin resistance syndromes 2—conditions requiring endocrine management
Comprehensive Hormonal Assessment Needed: The guidelines specify that proper androgen evaluation requires 1:
- Total testosterone using LC/MS (not standard immunoassays, which lack accuracy in female ranges)
- Free testosterone via equilibrium dialysis or calculated using SHBG
- Additional screening: DHEAS, 17-hydroxyprogesterone, thyroid function, prolactin, iron studies, vitamin D, and zinc 1
Most primary care settings lack access to these specialized assays and the expertise to interpret borderline results in the context of hair loss.
What Endocrinology Will Evaluate
Rule Out Serious Pathology:
- Androgen-secreting tumors (ovarian or adrenal)
- Non-classic congenital adrenal hyperplasia
- Cushing syndrome
- Severe insulin resistance syndromes
- PCOS with metabolic complications
Optimize Treatment Strategy: When hyperandrogenism is confirmed, combination therapy with antiandrogens or 5α-reductase inhibitors may be indicated alongside topical minoxidil 1. These systemic therapies require:
- Strict contraception counseling (teratogenic risk)
- Monitoring for side effects
- Dose optimization based on severity
Common Pitfall to Avoid
Do not assume elevated DHT is clinically insignificant. Research shows that while DHT levels may not always correlate with alopecia severity 3, 4, the presence of biochemical hyperandrogenism changes the diagnostic and therapeutic approach. Approximately 40% of women with FPHL report menstrual irregularities, hirsutism, or acne 4, suggesting underlying endocrine dysfunction requiring specialized management.
Management While Awaiting Referral
- Initiate topical minoxidil 5% (foam or solution) as first-line therapy 1—this can begin immediately and does not require endocrine clearance
- Document any signs of virilization: hirsutism, acne, menstrual irregularities, voice deepening
- Check if patient desires pregnancy soon (affects antiandrogen eligibility)
The endocrinologist will determine whether systemic antiandrogen therapy is appropriate after excluding serious pathology and assessing the full hormonal profile with high-quality assays.